Janssen is spearheading a new era for pulmonary hypertension (PH), working to transform the disease into a long-term manageable condition, so that patients can live a normal life.
We are focusing our scientific and commercial expertise to help raise the bar in the management of PH, using the combined skills and resources we now have to build on current PH initiatives and pursue new opportunities to improve diagnosis, access to therapy and patient outcomes.
Supported by Actelion’s more than 20-year heritage of pioneering innovation, we bring to the field of PH a remarkable track record in scientific discovery and a deep patient-centric focus, underpinned by an open, transparent business culture.
In order to build on this legacy, we are looking to harness advanced technologies through partnerships – in every area from data analytics to artificial intelligence, blood-based biomarkers and non-invasive imaging – so that together, we might better identify patients and accelerate diagnosis.
If you have a licensing candidate or program idea that you feel may be of interest to Janssen Research & Development, LLC, we invite you to submit this idea on the contact form located here.